Wells Fargo & Company Exelixis, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Exelixis, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 94,410 shares of EXEL stock, worth $2.21 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
94,410
Previous 56,151
68.14%
Holding current value
$2.21 Million
Previous $1.35 Million
66.3%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding EXEL
# of Institutions
463Shares Held
247MCall Options Held
1.7MPut Options Held
1.02M-
Black Rock Inc. New York, NY34.9MShares$816 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA30.8MShares$721 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA26.7MShares$624 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.1MShares$353 Million0.56% of portfolio
-
State Street Corp Boston, MA13.1MShares$306 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $7.53B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...